O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts

British Journal of Cancer

Volumn 93, Issue 10, 2005, Pages 1152-1156

  Clemons, M ^a,b,d   Kelly, J ^a   Watson, A J ^a   Howell, A ^b   McElhinney, R S ^c   McMurry, T B H ^c   Margison, G P ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Breast cancer; Breast tumour xenografts; MCF 7; MGMT; Temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; GUANINE DERIVATIVE; LOMEGUATRIB; O 6 (4 BROMOTHIENYL)GUANINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; DACARBAZINE; DRUG DERIVATIVE; GUANINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; O(6) (4 BROMOTHENYL)GUANINE; O(6)-(4-BROMOTHENYL)GUANINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; XENOGRAFT; ANIMAL; BODY WEIGHT; BREAST TUMOR; CELL PROLIFERATION; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BODY WEIGHT; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GUANINE; HUMANS; MALE; MICE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27944498276     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602833     Document Type: Article

References (39)

1. Antman KH (2001) Randomized trials of high dose chemotherapy for breast cancer. Biochim Biophys Acta 1471: 89-98
2. Bengala C, Pazzagli I, Innocenti F, Donati S, Favre C, Menconi MC, Greco F, Danesi R, Orlandini C, Guarneri V, Del Tacca M, Conte PF (2001) High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). Ann Oncol 12: 69-74
3. 6-methylguanine acceptor protein in extracts of human breast tumour tissues. Cancer Biochem Biophys 121: 53-58
4. Carmichael J, De Giagg WG, Gazdav AF, Mina JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay; assessment of chemosensitivity testing. Cancer Res 47: 936-942
5. Chen JM, Zhang YP, Wang C, Sun Y, Fujimoto J, Ikenega M (1992) O6-methylguanine-DNA methyltransferase activity in human tumours. Carcinogenesis 13(9): 1503-1507
6. 6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood 89: 1566-1573
7. Citron M, Schoenhaus M, Rothenberg H, Kostroff K, Wasserman P, Kahn L, White A, Burns G, Held D, Yarosh D (1994) O6-methylguanine-DNA methyltransferase in normal and malignant-tissue of the breast. Cancer Invest 12: 605-610
8. 6-alkylguanine DNA-alkyltransferase expression in human breast tumours. Br J Cancer 86: 1797-1802
9. Clemons MJ, Leahy MG, Valle J, Jayson G, Ranson M, Hayes S, Howell A (1997) Review of recent trials for advanced breast cancer. Part I: Studies excluding taxanes. Eur J Cancer 33: 2171-2182
10. Clemons M, Ranson M, Margison JM, El Teraifi H, Griffiths A, Kelly J, Morris CQ, Howell A, Margison GP (2003) Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide- bischloroethylnitrosourea combination therapy in patients with advanced breast cancer. Int J Cancer 103: 686-692
11. Clemons M, Watson A, Howell A, Chang J, Heyworth C, Lord B, Testa N, Dexter TM, Margison G (2000) Macrophage inflammatory protein !alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte - macrophage colony-forming cells. Clin Cancer Res 6: 966-970
12. 6-Benzylguanine and its role in chemotherapy. Clin Cancer Res 16: 837-847
13. 6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp Haematol 23: 112-116
14. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 18: 3522-3528
15. Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20: 2388-2399
16. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4: 296-307
17. Hammond LA, Eckardt JR, Kuhn JG, Gerson SL, Johnson T, Smith L, Drengler RL, Campbell E, Weiss GR, Von Hoff DD, Rowinsky EK (2004) A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res 10: 1645-1656
18. Kiebert GM, Jonas DL, Middleton MR (2003) Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 21: 821-829
19. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer 67: 216-221
20. 6-alkylguanine-DNA alkyltransferase. Carcinogenesis 24: 625-635
21. 6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays 24: 255-266
22. 6-methylguanine. Mutagenesis 17: 483-487
23. 6-alkylguanine-DNA alkyltransferase. 1. Novel O6-(hetarylmethyl)guanines having basic rings in the side chain. J Med Chem 41(26): 5265-5271
24. Micetich KC, Futscher B, Koch D, Fisher RI, Erickson LC (1992) Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer. J Natl Cancer Inst 84: 256-260
25. Middleton MR, Kelly J, Thatcher N, Donnelly DJ, McElhinney RS, McMurry TB, McCormick JE, Margison GP (2000) O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer 85(2): 248-252
26. Middleton MR, Margison GP (2003) Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol 4: 37-44
27. 6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model. Int J Cancer 100(5): 615-617
28. 6- alkylguanine DNA alkyltransferase activity levels in normal, benign and malignant human female breast. Biochem Biophys Res Commun 208: 688-696
29. National Cancer Institute of Canada (2001) Phase II study of temozolomide given in a 7 days on, 7 days off oral schedule to patients with advanced breast cancer. http://www.ctg.queensu.ca/public/Clinical_Trials/ind_trial_summ.htm #breast
30. 6-alkylguanine-DNA alkyltransferase: regulation and Importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129
31. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51: 167-223
32. Peters WP, Ross M, Vredenburgh JJ, Hussein A, Rubin P, Dukelow K, Cavanaugh C, Beauvais R, Kasprzak S (1994) The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 21(4 Suppl 7): 25-31
33. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon II JE, Bigner DD, Friedman HS (2002) Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20: 2277-2283
34. 6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 6: 3025-3031
35. 6-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 2: 1129-1134
36. 6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 59: 2402-2410
37. van Brussel JP, Busstra MB, Lang MS, Catsburg T, Schroder FH, Mickisch GH (2000) A phase II study of temozolomide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 45: 509-512
38. 6-alkylguanine-DNA alkyltransferase assay. Methods Mol Biol 152: 49-61
39. 6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 40: 266-272